Atypical agents have emerged as clear winners in the antipsychotic market, garnering more than 80% of sales in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) in 2000. Overview of Antipsychotics, a new study from Decision Resources, Inc., examines the market for antipsychotics to treat schizophrenia, bipolar disorder (BPD), and other psychotic disorders.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Broader On- and Off-Label Use Expands the Market
Substantial growth is expected in on- and off-label use of atypical agents in the treatment of bipolar disorder over the 2000-2010 forecast period of this study. By the second half of the study period, olanzapine (Eli Lilly's Zyprexa) could be approved for long-term prophylaxis in BPD, if investigations confirm its long-term efficacy.
Decision Resources also expects risperidone (Janssen's Risperdal) to achieve significant gains in the BPD market. This drug is expected to be approved for the treatment of BPD by 2003 in the United States and in Europe and will compete head-to-head with olanzapine. Ziprasidone (Pfizer's Geodon/Zeldox) and quetiapine (AstraZeneca's Seroquel) will also compete effectively in the BPD arena, possibly taking market share from olanzapine if they are shown to be efficacious for manic symptoms.
New Avenues for Commercial Success
The availability of atypical agents in short-acting intramuscular (IM) formulations will expand the use of these drugs in acute settings. The commercial benefit of this strategy lies in the likelihood that physicians will opt to continue patients on an oral or depot version of the same drug that is administered in the acute setting.
The report projects that sales of antipsychotic medications will surpass $8.1 billion in 2005, with growth being driven primarily by continued transition from generically available typical antipsychotics to more expensive atypical agents and increased use of atypical antipsychotics in nonschizophrenic indications. The United States is the strongest and most dynamic market for the higher-cost atypical antipsychotics, but acceptance of these more tolerable drugs is growing in Europe. The Japanese market will evolve dramatically over the next five years as more atypical agents are launched.
Overview of Antipsychotics offers invaluable market intelligence for pharmaceutical companies competing in this market. This study is part of Cognos, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources
Contact: Frank Sama of Decision Resources, +1-781-296-2553,